PGR and neoplasm: Among subgroups, the largest treatment benefit was observed in patients with high-grade tumor (HR, 0.322; 95% CI, 0.190–0.546), TFI < 36 months (HR, 0.418; 95% CI, 0.240–0.729), PgR status negative (HR, 0.427; 95% CI, 0.265–0.687), or presence of liver metastasis (HR, 0.449; 95% CI, 0.259–0.777; Fig. 1b).